NEW YORK (TheStreet) -- Sequenom, Inc.
(SQNM) shares finished trading Monday up 9.1% to $3.34 following news that the company gained pre-market FDA clearance for its IMPACT genotyping test.
The noninvasive prenatel test analyzes chromosonal material in cell free DNA for pregnant women at an increased risk for fetal chromosonal abnormalities.
The San Diego-based company formed a licencing agreement with Quest Diagnostics (DGX) -- expected to make the test available by the third quarter-- to expand patient access to the test.
Must Read: Warren Buffett's 25 Favorite Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts